Series A financing disclosure · Biotech

Marrow Therapeutics discloses $53m Series A led by Scion and venBio

The earlier round was disclosed alongside a separate $120m Series B as Marrow unveiled its bone marrow-targeted medicines platform.

Marrow Therapeutics disclosed a $53 million Series A co-led by Scion Life Sciences and venBio on 17 November 2026. The company announced the earlier financing alongside a separate $120 million Series B. Together, the rounds fund development of genetic medicines for severe blood disorders.

Use of funds

Develop bone marrow-targeted genetic medicines

Advance MAR-101 toward clinical development

Funding history

Series A financing disclosure · This round$53M

Sources

  1. Marrow Therapeutics Launches with $173 Million to Develop Genetic Medicines for Bone Marrow Disordersmarrowtx.com · Nov 17, 2026